Inventor · Woodside, CA, US

Bryan Irving

14Patents
6h-index
32Co-inventors
62Inventor score

Filing activity: Dec 8, 2009 → Oct 25, 2023

Most-cited inventions

PatentTitleAreaCited byStatus
US8217149B2 Anti-PD-L1 antibodies, compositions and articles of manufacture Emerging Cross-Sectional Technologies 385 Active
US9920123B2 Anti-PD-L1 antibodies, compositions and articles of manufacture Emerging Cross-Sectional Technologies 27 Active
US9873740B2 Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors Emerging Cross-Sectional Technologies 18 Active
US10669337B2 Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same Chemistry; Metallurgy 18 Active
US9724413B2 Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors Human Necessities 15 Active
US11161906B2 Multispecific antibodies, multispecific activatable antibodies and methods of using the same Chemistry; Metallurgy 7 Active
US10626174B2 Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors Emerging Cross-Sectional Technologies 3 Active
US10611836B2 Methods of treating cancer using PD-1 axis binding antagonists and tigit inhibitors Emerging Cross-Sectional Technologies 2 Active
US9895441B2 Methods of treating cancer using PD-L1 axis binding antagonists and VEGF antagonists Human Necessities 2 Active
US10646567B2 Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors Human Necessities 1 Active
US11472889B2 Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof Chemistry; Metallurgy 1 Active
US11859010B2 Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof Chemistry; Metallurgy 0 Active
US12215156B2 HER-2 targeted bispecific compositions and methods for making and using the same Chemistry; Metallurgy 0 Active
US11802158B2 Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same Chemistry; Metallurgy 0 Active

Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.